Search

Search Constraints

You searched for: Author/Creator Slee, Mark

Search Results

1. 008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. (23rd August 2021)

2. 010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort. (23rd August 2021)

5. A new era in the treatment of multiple sclerosis. Issue 3 (3rd August 2015)

6. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study. (14th June 2022)

7. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. (October 2018)

8. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis. (August 2015)

9. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Issue 12 (19th October 2022)

10. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Issue 4 (13th January 2019)